These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21105130)

  • 21. Neurobiology and treatment of Parkinson's disease.
    Schapira AH
    Trends Pharmacol Sci; 2009 Jan; 30(1):41-7. PubMed ID: 19042040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.
    Marras C; Lang AE
    Expert Rev Neurother; 2004 Nov; 4(6):985-93. PubMed ID: 15853525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial designs used to study neuroprotective therapy in Parkinson's disease.
    Lang AE; Melamed E; Poewe W; Rascol O
    Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical importance of neuroprotection in Parkinson's disease.
    Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
    J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.
    Quik M; O'Neill M; Perez XA
    Trends Pharmacol Sci; 2007 May; 28(5):229-35. PubMed ID: 17412429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
    Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression.
    Youdim MB; Grünblatt E; Levites-Royak Y; Mandel S
    Adv Neurol; 2001; 86():115-24. PubMed ID: 11553968
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
    LeWitt PA
    J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M; Maruyama W
    Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
    Hälbig TD; Tse W; Olanow CW
    Neurol Clin; 2004 Oct; 22(3 Suppl):S1-S17. PubMed ID: 15501359
    [No Abstract]   [Full Text] [Related]  

  • 32. The management of patients with early Parkinson's disease.
    Rascol O; Brefel-Courbon C; Payoux P; Ferreira J
    Adv Neurol; 2003; 91():203-11. PubMed ID: 12442679
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of Parkinson's disease a review of current and new therapies.
    Mendis T; Suchowersky O; Lang A; Gauthier S
    Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotection in Parkinson disease.
    Simpkins N; Jankovic J
    Arch Intern Med; 2003 Jul; 163(14):1650-4. PubMed ID: 12885679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
    Lindvall O; Wahlberg LU
    Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Parkinson's disease--new horizons].
    Bötzel K
    MMW Fortschr Med; 2004 Mar; 146(10):21-3. PubMed ID: 15347072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.